Table 1.
All patients | VKA-ICH | DOAC-ICH | ||
---|---|---|---|---|
Characteristics | (n=102) | (n=77) | (n=25) | P-value |
Age, years | 79 (71–84) | 80 (72–85) | 78 (68.5–82) | 0.141 |
Age, >75 years old | 70 (68.6) | 54 (70.1) | 16 (64) | 0.623 |
Female sex | 42 (41.2) | 33 (42.9) | 9 (36.0) | 0.643 |
Weight, kg | 82.7 (68.1–113.4) | 80.5 (66.5–93.4) | 89.0 (73.7–104.9) | 0.053 |
Admission GCS | 13 (7–15) | 12 (6–15) | 14 (10–15) | 0.334 |
Admission NIHSS | 13 (4–25) | 14 (4–28) | 10 (3–22) | 0.436 |
SBP on admission, mmHg | 172 (151–203) | 173 (148–204) | 168 (160–203) | 0.966 |
DBP on admission, mmHg | 91 (73–105) | 91 (71–103) | 89 (75–112) | 0.898 |
Preexisting risk factors | ||||
Hypertension | 99 (97.1) | 74 (96.1) | 25 (100.0) | 0.574 |
Diabetes | 36 (35.3) | 26 (33.8) | 10 (40.0) | 0.633 |
Prior stroke or TIA | 31 (30.4) | 22 (28.6) | 9 (36.0) | 0.617 |
Coronary artery disease | 42 (41.2) | 33 (42.9) | 9 (36.0) | 0.643 |
Hyperlipidemia | 72 (70.6) | 51 (66.2) | 21 (84.0) | 0.129 |
Atrial fibrillation | 92 (90.2) | 67 (87.0) | 25 (100.0) | 0.114 |
Preadmission medications | ||||
Statin | 70 (68.6) | 52 (67.5) | 18 (72.0) | 0.854 |
Antihypertensive | 97 (95.1) | 73 (94.8) | 24 (96.0) | 1.000 |
Antiglycemic | 26 (25.5) | 21 (27.3) | 5 (20.0) | 0.601 |
Antiplatelets | 41 (40.2) | 30 (39.0) | 11 (44.0) | 0.815 |
Laboratory data | ||||
Creatinine, mg/dL | 0.9 (0.8–1.4) | 1.0 (0.8–1.4) | 0.94 (0.8–1.2) | 0.747 |
GFR, ml/min/1.73 m2 | 63 (45–88) | 60 (41–86) | 69 (56–93) | 0.105 |
GFR <30 ml/min/1.73 m2 | 9 (8.8) | 9 (11.7) | 0 (0.0) | 0.108 |
PLT, 103cells/μL | 186 (151–233) | 187 (149–236) | 185 (165–233) | 0.481 |
Random glucose, mg/dL | 138 (109–177) | 138 (111–176) | 137 (105–192) | 0.762 |
Targeted reversal strategy used | 74 (72.5) | 72 (93.5) | 2 (8.0) | <0.001 |
Any reversal strategy used | 89 (87.3) | 72 (93.5) | 17 (68.0) | 0.003 |
Reversal strategies used | ||||
Vitamin K | 67 (65.7) | 66 (85.7) | 1 (4.0) | <0.001 |
Fresh frozen plasma | 43 (42.2) | 43 (55.8) | 0 (0.0) | <0.001 |
Prothrombin complex concentrate | 33 (32.4) | 18 (23.4) | 15 (60.0) | 0.001 |
Recombinant activated factor VII | 43 (42.2) | 29 (37.7) | 0 (0) | <0.001 |
Idarucizumab | 2 (2.0) | 0 (0.0) | 2 (8.0) | 0.058 |
Radiological characteristics | ||||
Supratentorial hemorrhage | 78 (76.5) | 56 (72.7) | 22 (82.0) | 0.175 |
Lobar hemorrhage | 47 (46.1) | 34 (44.2) | 13 (52.0) | 0.645 |
IVH present | 46 (45.1) | 35 (45.5) | 11 (44) | 1.000 |
Data are n (%) or median (25th–75th quartile); DBP=Diastolic blood pressure; DOAC-ICH=direct oral anticoagulation related intracerebral hemorrhage; GCS=Glasgow coma scale, GFR=Glomerular filtration rate; IVH=intraventricular hemorrhage; PLT=platelet count; SBP=Systolic blood pressure; TIA=transient ischemic attack; VKA-ICH=vitamin K antagonist related intracerebral hemorrhage.